Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Josep Brugada
Prof. Salim Yusuf,
Presenter | see Discussant report
Salim Yusuf, FESC (Canada)Presentation webcast
List of Authors: S. Yusuf and S. Connolly on behalf of the ACTIVE Investigators. Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada Abstract: One of the strongest risk factors for the development of atrial fibrillation (AF) is elevated blood pressure (BP). Stroke and heart failure which are common complications of AF are also related to elevated BP. Small trials have suggested that blockade of RAAS may be beneficial in AF. However, BP lowering or blockade of the renin-angiotensin-aldosterone system (RAAS) have not been studied in large trials of patients with AF. We evaluated the comparative effects of irbesartan, an angiotension receptor blocker, (target dose 300mg/day) or placebo given for a mean of 4.1 years, in reducing major vascular events (CV death, MI or stroke: first co-primary) and heart failure (CV death, MI stroke: second co-primary) in 9016 patients with AF receiving usual care. These patients were drawn from two parallel trials (ACTIVE-A and ACTIVE-W) involving over 14,000 patients utilizing a partial factorial design. BP at entry was 138/75 mm Hg; mean age was 69.5 years. The reduction in BP was modest (-2.6/-1.9 mm Hg) with irbesartan compared to placebo. Irbesartan did not reduce the risk of the first co-primary outcome of CV death, myocardial infarction or stroke (5.4% per year in each group), but there was a lower rate of the second co-primary CV death, MI, stroke and heart failure hospitalizations (7.3% vs 7.7% p= 0.12) with irbesartan, which was chiefly due to a significant reduction in the risk of heart failure hospitalization (3.2% per year in the placebo group versus 2.7% with irbesartan by 14%, p= 0.018). Recurrent event analysis of the second co-primary (39.6% with irbesartan vs. 44.3% with placebo) indicated clearer differences (RR = 0.89, CI = 0.82 to 0.98 ; p = 0.06). Post hoc analysis indicated a significant reduction in the risk of the composite of stroke, non-central nervous system embolism and transient ischemic attacks (3.4% per year in the placebo group versus 2.9% with irbesartan) by 13% (p=0.02), with consistently lower rates of each component of the composite. The number of admissions in hospital (4055 placebo vs. 3816 irbesartan; p= 0.004) and days hospitalized for cardiovascular reasons were significantly reduced (39,941 placebo vs. 36,480 irbesartan; p=0.0001). Irbesartan was well tolerated with similar rates of drug discontinuation compared to placebo. Conclusions The modest BP lowering achieved with irbesartan in this “normotensive” population with AF was associated with reductions in heart failure hospitalizations and thromboembolic events, but not in death or myocardial infarction. These findings suggest that the impact of larger degrees of BP lowering are worth exploring and may potentially lead to larger reductions in thromboembolic events and heart failure.
Discussant | see Presenter abstract
Josep Terradellas, FESC (Spain)
A randomized evaluation of irbesartan versus placebo in patients with Atrial Fibrillation (factorial design of ACTIVE Program)
This congress report accompanies a presentation given at the ESC Congress 2009. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.
© 2017 European Society of Cardiology. All rights reserved